You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(04.26)︱復星醫藥一季度淨利潤8.47億元;永達汽車一季度純利大增786.2%
格隆匯 04-26 23:21

【財務數據】

復星醫藥(02196.HK)一季度淨利潤8.47億元 同比增長46.78%

永達汽車(03669.HK)一季度業績亮眼:歸母淨利潤5.26億元 同比大增786.2%

金風科技(02208.HK)一季度歸母淨利9.72億元 同比增加8.62%

東方證券(03958.HK)一季度淨利潤11.76億元 同比增長44.67%

億仕登控股(01656.HK)一季度淨利同比增長95.4%至610萬新元

廣州農商銀行(01551.HK)一季度實現淨利22.83億元

國信證券(002736.SZ)一季度淨利潤16.85億元 同比增長18.33%

中鋁國際(02068.HK)一季度實現淨利4735.90萬元 同比扭虧

中國智慧能源(01004.HK)2020年淨虧1.49億港元 同比擴大21.62%

鄭煤機(00564.HK)一季度淨利約5.56億元 同比增加38.42%

天業節水(00840.HK)一季度淨虧損274.8萬元

【業績預吿】

金泰豐國際控股(08479.HK)預期一季度扭虧為盈至不少於800萬元

阿仕特朗金融(08333.HK)預計一季度虧損410萬港元

【運營數據】

中國交通建設(01800.HK):一季度新籤合同額4105.88億元 同比增長80.30%

路勁(01098.HK)一季度銷售約152.68億元

百奧家庭互動(02100.HK)第一季度活躍賬户為1050萬 環比上升7%

【股本重組】

勝龍國際(01182.HK)建議實施股本重組

【併購出售】

匯森家居(02127.HK)擬2080萬元收購贛州一幅地塊 以建立新龍南製造工廠

復星醫藥(02196.HK):禪城醫院及復星醫療擬向豫園股份轉讓佛山禪曦100%股權及相關債權

錦藝集團控股(00565.HK)擬4.3億元出售鄭州佳潮物業服務75%股權

第七大道(00797.HK)擬1000萬元收購北京美麥科技全部股權

越秀地產(00123.HK)附屬競得廣州番禺地塊及廣州白雲地塊

中國汽車新零售(00526.HK)擬5500萬元出售寧波姜山鎮物業

增發供股】

創建集團控股(01609.HK)擬折讓約12.78%增發4549萬股 淨籌2.634億港元

【投資運營】

工商銀行(01398.HK)獲准參與投資國家綠色發展基金

華潤啤酒(00291.HK)擬出資1.5億元參與成立合夥企業

基石藥業-B(02616.HK):普拉替尼膠囊擴展適應症申請獲國家藥監局受理並被納入優先審評

中國能源建設(03996.HK)附屬參與設立項目公司負責保定市蓮池區11個城中村改造項目

君實生物(01877.HK):XPO1抑制劑JS110獲得藥物臨牀試驗批准通知書

君實生物(01877.HK):EGFR exon 20插入等非常見突變抑制劑JS111獲得藥物臨牀試驗批准通知書

澳能建設(01183.HK)完成曼克頓電動汽車充電基礎設施安裝

華僑城(亞洲)(03366.HK)擬成立合夥企業 參與粵港澳大灣區新型城鎮化項目

【回購註銷】

昊海生物科技(06826.HK)4月26日耗資1543.26萬港元回購23.32萬股H股

中國旺旺(00151.HK)4月26日耗資1903.75萬港元回購335萬股

復星國際(00656.HK)4月26日耗資1103.44萬港元回購100萬股

合生創展集團(00754.HK)4月26日耗資2485.31萬港元回購90.2萬股

【股權激勵】

中國動力控股(00476.HK)根據股份獎勵計劃發行4850萬股

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account